图书简介

Section 1: Universal definition of heart failure; 1.1 Andrew JS Coats, Biykem Bozkurt and Petar M. Seferovic: Universal definition of heart failure; Section 2: Epidemiology of heart failure; 2.1 Amy Groenewegen, Ivan Milinkovi?, Arno W Hoes, Arend Mosterd, Frans H Rutten: Epidemiology of heart failure; Section 3: Etiology of heart failure; 3.1 (Rocco Antonio Montone, Maurizio Volterrani, Jian Zhang and Filippo Crea: Coronary artery disease; 3.2 Athanasios Manolis and Yuri Lopatin: Hypertension; 3.3 Ana Pardo Sanz, Ivan Milinkovic and Josep Zamorano: Valvular heart disease; 3.4.1 Thomas Thum, Stephane Heymans, and Johannes Backs: Genetic basis of cardiomyopathies; 3.4.2 Petar M.Seferovic, Biykem Bozkurt, and Marija Polovina: Dilated and hypokinetic non-dilated cardiomyopathy; 3.4.3 Perry Elliott, Michel Noutsias and Aris Anastasakis: Hypertrophic cardiomyopathy; 3.4.4 Claudio Rapezzi, Alberto Aimo, Ales Linhart, and Andre Keren: Restrictive cardiomyopathy; 3.4.5 Cristina Basso, Hugh Calkins and Domenico Corrado: Arrhythmogenic right ventricular cardiomyopathy; 3.4.6 Karen Sliwa and Johann Bauersachs: Peripartum cardiomyopathy; 3.4.7 Jelena Templin-Ghadri, Michael Wurdinger, Johann Bauersachs, and Christian Templin: Takotsubo cardiomyopathy; 3.5 Stephane Heymans, Arsen Risti?, Yehuda Adler, and Massimo Imazio: Myocarditis and pericarditis; 3.6 Werner Budts and Jolien Roos-Hesselink: Congenital heart disease; 3.7 Martin Huelsmann, Jelena Seferovic and Francesco Cosentino: Endocrine and metabolic disorders; 3.8 Lina Badimon, Stefan Anker and Stephan von Haehling: Obesity; 3.9 Alexander Lyon, Dimitrios Farmakis, Daniela Cardinale and Teresa Lopez Fernandez: Cancer and cancer therapy; 3.10 Antonello Gavazzi, Maria Nunes, and Fausto Pinto: Toxins (e.g. alcohol etc.) and infections; Section 4: Prevention of heart failure; 4.1 Massimo Piepoli, Maria Benedetta Matrone, Paul Dendale, and Shelley Zieroth: Prevention of heart failure; Section 5: Pathophysiology of heart failure; 5.1 (Junjie Xiao, Thomas Thum, Gianluigi Condorelli and Johannes Backs: Molecular and cellular mechanisms; 5.2 Edoardo Bertero and Chistoph Maack: Alterations in myocardial metabolism; 5.3 Javier Diez Martinez and Hans-Peter Brunner La Rocca: Ventricular remodelling; 5.4 Antoni Bayes Gennis and Faiez Zannad: Neurohormonal activation; 5.5 Urlich Hofmann, Stefan Frantz and Nikolaos Frangogiannis: Immune-mediated mechanisms; 5.6 Stephane Heymans: Inflammation, oxidative stress and endothelial dysfunction; 5.7 Alterations in peripheral circulation and renal function (: Alterations in peripheral circulation and renal function; 5.8 (Stephan von Haehling and Wolfram Doehner: Systemic adaptations in metabolism and nutritive status; Section 6: Clinical phenotypes of chronic heart failure; 6.1 Thomas Luscher, Petar Seferovic, and Brian Halliday: HFrEF; 6.2 Adrian Voors, Brenda Moura, Lars Lund and Carolyn Lam: HFmrEF; 6.3 Rudolf De Boer, Burkert Pieske, and Barry Borlaug: HFpEF; 6.4 Thomas Luscher, Thomas M. Gorter, Susanna Price, Michael Gatzoulis and Anneline Te Riele: Right heart failure; Section 7: Chronic heart failure: diagnostic and prognostic assessment; 7.1 Michel Komajda, Piotr Ponikowski, and Evgeny Shlyakhto: Clinical assessment; 7.2 Rudolf de Boer, Antioni Bayes Genis and James Januzzi: Biomarkers in diagnostic and prognostic assessment; 7.3 Philippe Debonnaire, Victoria Delgado, Thor Edvardsen, Bogdan Popescu, and Jeroen Bax: Echocardiography; 7.4 Danilo Neglia and Alessia Gimelli: Nuclear medicine; 7.5 Stephan Achenbach and Amina Rakisheva: Cardiac computed tomography; 7.6 Anna Baritussio, Noor Sharrack, Sven Plein, and Chiara Bucciarelli-Bucci: Cardiac magnetic resonance; 7.7 Luca Moderato, Davide Lazzeroni, Stamatis Adamopoulos, Alain Cohen-Solal and Massimo Piepoli: Cardiopulmonary exercise; 7.8 Christian Hamm, Brigit Assmus and Veselin Mitrovic: Cardiac catheterization, invasive imaging and haemodynamic assessment; Section 8: Chronic heart failure: pharmacological management; 8.1 Roberto Ferrari, Gabriele Guardigli, and Biykem Bozkurt: Angiotensin converting enzyme inhibitors; 8.2 Ileana L. Pina and Magdy Abdelhamid: Angiotensin I receptor blockers; 8.3 Petar M. Seferovic, Michele Senni, Marija Polovina and Andrew JS Coats: ARNI; 8.4 Daniela Tomasoni, Marianna Adamo, Hiroyuki Tsutsui, and Marco Metra: Beta-blockers; 8.5 Bertram Pitt, Joao Pedro Ferreira and Faiez Zannad: Mineralocorticoid receptor agonists; 8.6 Michael Bohm and Michel Komajda: Ivabradine; 8.7 Eftihia Polyzogopoulou, Maria Nikolaou, John Parissis and Alexandre Mebazaa: Vasodilators; 8.8 Udo Bavendiek and Johann Bauersachs: Digitalis glycosides; 8.9 Jeroen Dauw, Stephen Gottlieb and Wifried Mullens: Diuretics; 8.10 Jan Biegus, Piotr Ponikowski, and Christoph Maack: Inotropes and inodilators; 8.11 Petar M. Seferovic, Francesco Cosentino, Giuseppe Rosano and James Januzzi: SGLT2 inhibitors; 8.12 Stefan Agewall, Isabelle van Gelder, and Irene Savelieva: Ancillary pharmacological treatment options; 8.13 Giuseppe Rosano, Gerasimos Filippatos, and Randall Starling: New and emerging therapies; Section 9: Chronic heart failure: non-pharmacological management; 9.1 Gianluigi Savarese, Cecilia Linde and Kenneth Dickstein: Implantable cardioverter defibrillator; 9.2 Pieter Martens, Eva Goncalvesova, and Wilfried Mullens: Cardiac resynchronization therapy; 9.3 Felix Schoenrat, Franz-Josef Neumann, Miguel Sousa Uva and Volkmar Falk: Cardiac surgery; 9.4 Stefan Orwat, Stefan Anker and Helmut Baumgartner: Valve interventions; 9.5 Andrew JS Coats, Piotr P Ponikowski, Maria-Rosa Costanzo and William T. Abraham: Ancillary procedures; 9.6 Maurizio Volterrani, Alain Cohen-Solal, Stamatis Adamopulos, Dimitris Miliopoulos, Ferdinando Iellamo, and Massimo Piepoli: Cardiac rehabilitation; Section 10: Acute heart failure; 10.1 Ovidiu Chioncel, Gerasimos Filippatos, Alexandre Mebazaa, Veli-Pekka Harjola, and Josep Masip: Acute heart failure: diagnostic and prognostic assessment; 10.2 Katerina Fountoulaki, John Parissis, Sean Collins, Mehmet Birhan Yilmaz, and Alexandre Mebazaa: Acute heart failure: management; Section 11: Advanced heart failure; 11.1 Tuvia Ben Gal, Mariell Jessup, and Maria-Rosa Costanzo: Advanced heart failure: assessment; 11.2 Daniela Tomasoni, Marianna Adamo, and Marco Metra: Advanced heart failure: management; 11.3 Mandeep Mehra and Finn Gustafsson: Mechanical circulatory support; 11.4 Davor Milicic, Mandeep Mehra, and Randall Starling: Heart transplantation; 11.5 Tiny Jaarsma, Donna Fitzsimons, Lisa Hjelmfors, Loreena Hill, Ekaterini Lambrinou, and Anna Stromberg: Palliative care and end-of-life management; Section 12: Comorbidities and clinical conditions; 12.1 Pieter Martens and Hans-Peter Brunner-La Rocca: Chronic kidney disease: Clinical Aspects of Chronic Kidney Disease in Heart Failure; 12.2 Javed Butler, Wilfried Mullens and Kevin Damman and Joao Pedro Ferreira: Dyskalaemia; 12.3 Josep Masip, Karina Portillo and Mattia Arrigo: Chronic lung disease; 12.4 Piergiuseppe Agostoni, Elisabetta Salvioni, Maria Rosa Costanzo, and Andrew JS Coats: Ventilatory Abnormalities and Sleep Disordered Breathing; 12.5 Irene M. Lang and Stephan Rosenkranz: Pulmonary hypertension; 12.6 Silvia Priori, Alessandro Trancuccio, Alessia Chiara Latini, Carlo Arno, Deni Kukavica, and Andrea Mazzanti: Cardiac rhythm disorders; 12.7 Paulus Kirchhof, Andreas Metzner, Ruben Schleberger and Douglas Packer: Management of atrial fibrillation in heart failure; 12.8 Giuseppe Rosano, Javed Butler, Petar M. Seferovi?, Jelena Seferovic and Francesco Cosentino: Diabetes, metabolic syndrome and endocrine disorders; 12.9 Giacomo De Luca, Luca Moroni, Alessandro Tomelleri, R Marcolongo, Lorenzo Dagna, Alida LP Caforio, and Marco Matucci-Cerinic: Systemic immune medicated diseases; 12.10 Yuri Lopatin and Gianluigi Savarese: Liver and gut dysfunction; 12.11 Ewa Jankowska, Piotr Ponikowski, and Stefan Anker: Anaemia and iron deficiency; 12.12 Wolfram Doehner, Cristiana Vitale, and Mehmet Birhan Yilmaz: Depression and cognitive impairment; 12.13 Alexander Lyon, Dimitrios Farmakis, Rudolf de Boer, and Yuri Belenkov: Cancer; 12.14 Johann Bauersachs, Denise Hilfiker-Kleiner and Karen Sliwa: Pregnancy; 12.15 Ewa Jankowska, Cristiana Vitale and Dong-Ju Choi: Frailty; Section 13: Self-care and patient education; 13.1 Tiny Jaarsma, Loreena Hill, Ekaterini Lambrinou, Anna Stromberg, and Tina Hansen: Self-care and patient education; Section 14: Multidisciplinary approach to heart failure management; 14.1 Loreena Hill, Friedrich Koehler, Tiny Jaarsma, Marija Polovina, Katherine McCreary, and Andrew JS Coats: Multidisciplinary approach to heart failure management; Section 15: Clinical trial design and interpretation; 15.1 Gianluigi Savarese, Marija Polovina and Gerasimos Filippatos: Clinical trial design and interpretation; Section 16: Digital health in heart failure; 16.1 Arvind Singhal and Martin Cowie: Digital health in heart failure; Section 17: Big data in heart failure; 17.1 Mamas Mamas and Dipak Kotecha: Big data in heart failure; Section 18: Telemedicine and remote monitoring; 18.1 Tarek Bekfani, Friedrich Koehler and William T. Abraham: Telemedicine and remote monitoring

Trade Policy 买家须知